T-knife is a T-cell receptor (TCR) company building a pipeline of innovative therapeutics for solid tumor patients and their families.  We leverage our proprietary transgenic mouse platform in order to produce fully human TCRs, naturally selected in vivo for high affinity and specificity, and to develop TCR therapies that target tumor-specific antigens.